Topline phase 2a data showed a 48.9% six-month progression-free survival rate with intranasal NEO100 in previously treated IDH1-mutant glioma.
Commentary|Videos|December 3, 2025
Dr Brown Discusses Neuroendocrine Tumors
Author(s)Rebecca Brown, MD, PhD
Rebecca Brown, MD, PhD, discusses neuroendocrine tumors.
Advertisement
Rebecca Brown, MD, PhD, discusses neuroendocrine tumors.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5